Effects of combination treatment of intravesical Resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial Cystitis

A pilot study

Byeong Kuk Ham, Jae Heon Kim, Mi-Mi Oh, Jeong Gu Lee, Jae Hyun Bae

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This prospective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment. Methods: Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale, the maximal urine flow rate, post-void residual urine volume, and a voiding diary before and 3 months after treatment. Results: The median age of the 18 patients was 55.8±6.9 years, and the median duration of symptoms before diagnosis was 3.6± 1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 3-month after treatment in both groups. Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale. Conclusions: Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving lower urinary tract symptoms. Further larger studies are needed to clarify the efficacy of combination treatment of intravesical RTX instillation and hydrodistention.

Original languageEnglish
Pages (from-to)41-46
Number of pages6
JournalInternational Neurourology Journal
Volume16
Issue number1
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

Intravesical Administration
Interstitial Cystitis
Pain
Therapeutics
Urinary Bladder
Urinary Bladder Diseases
Urine
Lower Urinary Tract Symptoms
Residual Volume
resiniferatoxin
Pain Measurement
Prospective Studies

Keywords

  • Interstitial cystitis
  • Intravesical administration
  • Pain
  • Resiniferatoxin

ASJC Scopus subject areas

  • Clinical Neurology
  • Urology
  • Neurology

Cite this

@article{acbf8c9a3a0d4267955e22b77933a804,
title = "Effects of combination treatment of intravesical Resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial Cystitis: A pilot study",
abstract = "Purpose: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This prospective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment. Methods: Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale, the maximal urine flow rate, post-void residual urine volume, and a voiding diary before and 3 months after treatment. Results: The median age of the 18 patients was 55.8±6.9 years, and the median duration of symptoms before diagnosis was 3.6± 1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 3-month after treatment in both groups. Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale. Conclusions: Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving lower urinary tract symptoms. Further larger studies are needed to clarify the efficacy of combination treatment of intravesical RTX instillation and hydrodistention.",
keywords = "Interstitial cystitis, Intravesical administration, Pain, Resiniferatoxin",
author = "Ham, {Byeong Kuk} and Kim, {Jae Heon} and Mi-Mi Oh and Lee, {Jeong Gu} and Bae, {Jae Hyun}",
year = "2012",
month = "3",
day = "1",
doi = "10.5213/inj.2012.16.1.41",
language = "English",
volume = "16",
pages = "41--46",
journal = "International Neurourology Journal",
issn = "2093-4777",
publisher = "Korean Association of Medical Journal Edirors",
number = "1",

}

TY - JOUR

T1 - Effects of combination treatment of intravesical Resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial Cystitis

T2 - A pilot study

AU - Ham, Byeong Kuk

AU - Kim, Jae Heon

AU - Oh, Mi-Mi

AU - Lee, Jeong Gu

AU - Bae, Jae Hyun

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This prospective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment. Methods: Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale, the maximal urine flow rate, post-void residual urine volume, and a voiding diary before and 3 months after treatment. Results: The median age of the 18 patients was 55.8±6.9 years, and the median duration of symptoms before diagnosis was 3.6± 1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 3-month after treatment in both groups. Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale. Conclusions: Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving lower urinary tract symptoms. Further larger studies are needed to clarify the efficacy of combination treatment of intravesical RTX instillation and hydrodistention.

AB - Purpose: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This prospective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment. Methods: Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale, the maximal urine flow rate, post-void residual urine volume, and a voiding diary before and 3 months after treatment. Results: The median age of the 18 patients was 55.8±6.9 years, and the median duration of symptoms before diagnosis was 3.6± 1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 3-month after treatment in both groups. Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale. Conclusions: Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving lower urinary tract symptoms. Further larger studies are needed to clarify the efficacy of combination treatment of intravesical RTX instillation and hydrodistention.

KW - Interstitial cystitis

KW - Intravesical administration

KW - Pain

KW - Resiniferatoxin

UR - http://www.scopus.com/inward/record.url?scp=84866918122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866918122&partnerID=8YFLogxK

U2 - 10.5213/inj.2012.16.1.41

DO - 10.5213/inj.2012.16.1.41

M3 - Article

VL - 16

SP - 41

EP - 46

JO - International Neurourology Journal

JF - International Neurourology Journal

SN - 2093-4777

IS - 1

ER -